Literature DB >> 8315599

Salivary autoantibodies in HIV-associated salivary gland disease.

J C Atkinson1, M Schiødt, S Robataille, D Greenspan, J S Greenspan, P C Fox.   

Abstract

A subset of HIV-positive patients develops salivary gland disease (HIV-SGD), characterized by salivary gland enlargement and/or decreased salivary flow. While clinical symptoms are similar to Sjögren's syndrome (SS), patients with HIV-SGD lack circulating anti-SS-A/Ro and anti-SS-B/La. Occasionally, SS patients lacking circulating anti-SS-A/Ro and anti-SS-B/La have these antibodies in their saliva. Salivas from 11 patients with HIV-SGD, 13 HIV+ patients without HIV-SGD, 14 HIV-negative men controls, and 11 patients with SS were screened for autoantibodies. Five HIV-SGD salivas had antibodies recognizing the cytoplasm of a salivary cell line. No HIV+ controls showed reactivity. Ten of 11 SS patients had salivary autoantibodies, and one HIV-negative control was positive for them. Salivary anti-SS-A/Ro was present in 8/11 SS patients, and 7 also contained anti-SS-B/La. No HIV-SGD salivary samples had these specific autoantibodies. These findings suggest that while glandular polyclonal expansion occurs in both HIV-SGD and SS, different autoantibodies are produced.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8315599     DOI: 10.1111/j.1600-0714.1993.tb01057.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  1 in total

1.  Salivary flow, amylase, and total protein in hospitalized patients with HIV infection / AIDS complications.

Authors:  Núbia Carina de Oliveira; Thayse Caroline de Oliveira; Vanessa Cavassin Klamas; Mateus Anhaia Ventura; Adryano Arana Kamei; Jhonatan Yukio Naka; João Armando Brancher; Antonio Adilson Soares de Lima
Journal:  Afr Health Sci       Date:  2020-06       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.